News | July 04, 2023
Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
One thousand times more soluble than L-cystine at neutral pH
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Subscribe To Our Newsletter & Stay Updated
